Indonesia warned about OTC sales of prescription drugs

9 April 2006

The Indonesian government should do more to monitor the sale and distribution of prescription drugs because of the over-the-counter availability of these products at local markets, according to Marius Widjajarta, head of the Indonesian Health Consumer Empowerment Foundation. Almost no monitoring by the country's Food and Drug Control Agency, the BPOM, exists, he told the Jakarta Post, noting that the agency only warned the public of the possible harm of buying these products without a prescription and did not do anything to stop their illegal sale and distribution.

In response, the BPOM issued a public warning stating that drugs which need a prescription were being sold in some stores as OTCs and that some of these were being marketed past their expiration dates or repackaged to change the date.

The consumer activist group derided the move, saying that the Agency should go beyond issuing warnings and look at the root of the problem. The BPOM needs to take action against retailers which sold drugs illegally, it said, adding that drugmakers should report their production quotas and where they distributed their drugs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight